HOME2019-03-11T17:27:49+00:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

Highlights of PD-MitoQUANT Plenary Meeting, November 20/21, 2019

November 28th, 2019|

At the sunny coastal town of Herzeliya, Israel, over 35 participants from 8 countries across Europe and Israel gathered for the 2nd plenary meeting of the PD-MitoQUANT IMI Consortium to discuss their latest progress toward investigating the role of mitochondrial dysfunction in Parkinson’s. Hosted by Teva Pharmaceutical Industries, researchers from [...]

Sandeep Chenna, RCSI presents PD-MitoQUANT at Molecular & Computational Biology Symposium, Dublin

November 26th, 2019|

The annual Molecular and Computational Biology Symposium took place at the Conway Institute of Biomolecular and Biomedical Research in University College, Dublin (UCD) on the 21st and 22nd of November 2019. The symposium which involved international keynote speakers was organised by Ph.D. students from Systems Biology Ireland, the School of [...]

Read more